“Herd” Immunity (Redux)

FromI AM BIO

Start listening View podcast show

“Herd” Immunity (Redux)

FromI AM BIO

ratings:

Length:

36 minutes

Released:

Jun 29, 2020

Format:

Podcast episode

Description

Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies?
Well, that’s where the super cows come in.

Hosted by Jim Greenwood.

Released:

Jun 29, 2020

Format:

Podcast episode

Titles in the series (100)

Powerful stories of biotechnology breakthroughs, the people they help, and the global problems they solve. Hosted by BIO President & CEO Dr. Michelle McMurry-Heath.

Skip carousel

Destroying COVID's Genome: Alnylam Pharmaceuticals, which take its name from the center and brightest star in Orion’s Belt, is working on an RNAi therapy to destroy the genome of the novel coronavirus — and with it, its ability to replicate and kill. Hosted by Jim Greenwood. by I AM BIO
39 min listen
“Herd” Immunity (Redux): Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
The Antibody Test Shortage: Only antibody testing can tell us who has been infected and recovered from coronavirus and when it might be safe to return to work. There’s a massive global shortage of these tests, and a Maryland biotech is racing to bolster the U.S. supply. Hosted by Jim Greenwood. by I AM BIO
27 min listen
An Alternative to Flying Dirty: While Swedish climate activist Greta Thunberg has kindled a global dialogue about the ravages of climate change and the role of airline emissions, a Colorado biotech is putting forward a jaw-dropping alternative to flight shaming: actual jet fuel with no carbon footprint. Hosted by Jim Greenwood. by I AM BIO
40 min listen
COVID-19 Could Generate 1st Computerized Vaccine: Futuristic biotech Moderna is the first to clinically test a coronavirus vaccine, created in weeks using only the virus’ genetic code. The company’s messenger RNA breakthrough may be just in time as a former CDC director warns that animal viruses spilling over to humans is the new normal. Hosted by Jim Greenwood. by I AM BIO
60 min listen
First Dose: One day before 16-year-old Izzy Thorpe-Wall takes her first dose of Vertex’s stunning Cystic Fibrosis breakthrough, Thorpe and her mother, Clare, open up about their emotional journey and one brave girl’s determination to stay healthy long enough to meet this day of her dreams. Hosted by Jim Greenwood. by I AM BIO
43 min listen
COVID-19: We Were Warned: For years, leaders on the Bipartisan Commission on Biodefense told Congress and the White House that it wasn’t a matter of if, but when, a pandemic would happen. Exploring the panel’s unheeded recommendations can give the United States a blueprint for what to do going forward to protect us from the coronavirus and future threats. Hosted by Jim Greenwood. by I AM BIO
50 min listen
Going Viral: Vir Biotechnology CEO George Scangos is the scientist selected by his peers to lead the biotechnology industry’s efforts to mitigate and ultimately end the pandemic. He explains how and why the novel coronavirus is so contagious and potentially dangerous to millions. Hosted by Jim Greenwood. by I AM BIO
23 min listen
COVID-19’s True Origins: There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Coronavirus Lung Treatment Could be Ready In Weeks: Regeneron’s rheumatoid arthritis drug shows promise to treat coronavirus-related lung syndrome and stop the inflammation that leads to death. The company also expects to test a preventative antibody shot in June. Hosted by Jim Greenwood. by I AM BIO
40 min listen
“Herd” Immunity: Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
New Trailer with Dr. Michelle: The I AM BIO podcast with host Dr. Michelle McMurry-Heath explores the search for biotechnology breakthroughs and our progress in ending the pandemic, helping patients and carrying the mantle for science and sustainability. by I AM BIO
2 min listen
Biotech's Finest Hour (Redux): As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
48 min listen
What Can Iceland Tell Us About COVID?: The people of Iceland — a country of 360,000 — eagerly volunteered for genetic research on how the coronavirus affects a homogeneous population. Amgen’s work in the Land of Fire and here at home could deliver answers and antibodies to help mitigate the pandemic threat. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID’s Essential Work: The physician-wife of Roivant Sciences CEO Vivek Ramaswamy rushed back to the front lines at the pandemic’s peak — less than a month after giving birth to the couple’s first son. Meanwhile, dad cared for their newborn while testing a promising therapeutic that seeks to overcome deadly cytokine storms caused by the novel coronavirus. Hosted by Jim Greenwood. by I AM BIO
30 min listen
Biotech’s Finest Hour: As the world waits for biotechnology to deliver COVID-19 treatments and a vaccine, Ambassador Deborah Birx tells BIO’s scientists: “Expectations are high because you’ve delivered for us before and I know that you can deliver for us again.” BIO chairman Jeremy Levin, a biotech pioneer, explains how the industry will rise to meet this moment. Hosted by Jim Greenwood. by I AM BIO
53 min listen
Trying our Patients: As genetic sequencing gives scientists new tools to hone in on medical mysteries, Washington politicians flirt dangerously with policies that would stymie the genomic revolution while giving patients scant pricing relief at the pharmacy counter. Hosted by Jim Greenwood. by I AM BIO
36 min listen
COVID-19’s True Origins (Redux): There's a joke among ecological health scientists that if “you don’t believe one person can change the world, try eating an undercooked bat.” However, what EcoHealth Alliance’s Dr. William Karesh — a world-renowned expert on zoonotic disease transmission — reveals about the trend line for animal-to-human viral transmission is no laughing matter. Hosted by Jim Greenwood. by I AM BIO
39 min listen
Superbuggin’: Incurable gonorrhea and the deadly hospital superbug C. diff offer a frightening window into the gathering public health menace of antibiotic resistance. If society doesn’t wake up and tackle the problem, we could be headed toward a calamity on the magnitude of climate change. Hosted by Jim Greenwood. by I AM BIO
28 min listen
COVID & the Plastics Problem: Fear and misinformation about how the coronavirus is transmitted has led to dangerous backsliding in society’s efforts to address plastic pollution. But we don’t have to lose this battle to win the COVID war. A Georgia biotech is first to market with a green biopolymer material that looks and feels like plastic but dissolves in ocean water. Hosted by Jim Greenwood. by I AM BIO
32 min listen
COVID X-FACTOR: The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We’ve evolved in this way as humans to ensure no virus can eradicate our species. Hosted by Jim Greenwood. by I AM BIO
32 min listen
Cancer in the COVID Era: Overcrowded hospitals during the pandemic can pose treatment challenges for patients with other serious illnesses. As Kite Pharma CEO Christi Shaw says, “Cancer doesn’t stop in a crisis.” Neither do her company’s employees, who go to extraordinary lengths to get personalized CAR-T treatments to patients around the world. Hosted by Jim Greenwood. by I AM BIO
20 min listen
Vaccines are a Virtue: As biotech researchers work around the clock on a covid vaccine, ill-informed, anti-science anti-vaxxers must be denounced and excoriated in the public square. BIO’s head of infectious disease policy Phyllis Arthur administers a vital dose of vaccine education, because none of us is safe until we all are. Hosted by Jim Greenwood. by I AM BIO
33 min listen
Sickle Cell Saviors: Need a dose of inspiration in a time of national tragedy? A remarkable biotech breakthrough from Global Blood Therapeutics offers fresh hope to patients living with sickle-cell disease. Hosted by Jim Greenwood. by I AM BIO
62 min listen
The Other Pandemic: Beating “Nightmare Bugs” (Part 2 of 2): Viral pandemics can lead to secondary bacterial infections that kill millions, Dr. Anthony Fauci concluded after studying the 1918 Spanish flu. A century later, COVID and antibiotic resistance are proving to be a lethal combination. What are the biopharma industry and Congress doing to keep your loved ones safe from superbugs? Hosted by Jim Greenwood. by I AM BIO
32 min listen
Vaccine Velocity: How can global nonprofits like the Center for Epidemic Preparedness Innovations (CEPI) deliver a safe and effective vaccine against the novel coronavirus in just 12 to 18 months when the world record for vaccine approval is four years? CEPI CEO Richard Hatchett, a 9/11 hero, says it’s all about smart planning. By the time governments give the green light on the safety and efficacy of a covid vaccine, manufacturer capacity will be pre-scaled up and able to quickly churn out doses by the tens or hundreds of millions. Hosted by Jim Greenwood. by I AM BIO
33 min listen
BONUS: Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala: We are on summer break as we work to bring you another exciting season this fall. So, for the next few weeks we’re sharing some of our favorite sessions from the June 2021 BIO Digital. Today, check out our session Breaking Barriers in Trade: A Conversation with Dr. Ngozi Okonjo-Iweala, Director-General, World Trade Organization. Speaker: Dr. Ngozi Okonjo-Iweala, World Trade Organization by I AM BIO
33 min listen
Respiratory Rescue?: The engine powering Maryland vaccine maker Novavax is a recombinant nanoparticle platform that is impressing vaccinologists as well as government and nonprofit funders. Learn about the innovative biotech generating big buzz in the global covid vaccine race. by I AM BIO
28 min listen
Can We Pass This COVID Test?: Millions of travelers ignored public health warnings and packed into airports over the holidays to see their loved ones. As a result, U.S. hospitals are bracing for the deadliest COVID surge yet this month. Meanwhile, Sherlock Biosciences, which has already made history once with CRISPR, seeks to do so again with an inexpensive, accurate home test that could be a global game-changer. by I AM BIO
36 min listen
Deep Diving for COVID Cures: By studying our earliest evolutionary ancestors in the ocean, marine biotech researchers are gaining fresh insights about everything from anti-virals to coronavirus nasal swab testing to the inner workings of our adaptive immune systems. Learn what sea sponges, lugworms and sharks can teach us about improving human health during this crisis. Hosted by Jim Greenwood. by I AM BIO
43 min listen

More Episodes from I AM BIO

Skip carousel

Listener takeover: Your Biotech Questions Answered: YOU asked, and we answered. In this episode, we had our experts on standby to answer questions from you, our listeners. We discuss topics ranging from the safety of genetically modified foods (GMOs), to the new era of personalized medicine, feeding the world by 2050, and even what makes start-up companies attractive to investors. by I AM BIO
21 min listen
Editing Cells Within the Body—a New CRISPR Frontier: With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body. We discuss the progress and the challenge in making this breakthrough a reality. by I AM BIO
21 min listen
Biotech is Climate Tech: Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech. by I AM BIO
21 min listen
Biotech for our Pets: More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries. by I AM BIO
28 min listen
What We Know About the Microbiome: The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits. by I AM BIO
27 min listen
Is CRISPR the New Sickle Cell Savior?: 2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. by I AM BIO
25 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection (REDUX): Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here (REDUX): Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death (REDUX): For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling (REDUX): The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech. (REDUX): Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab? (REDUX): The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
“On My Own”—Desperate to Stop a Resistant Bacterial Infection: Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace. by I AM BIO
28 min listen
The Synbio Revolution is Here: Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. by I AM BIO
26 min listen
How Biotechs Survive the Valley of Death: For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry. by I AM BIO
25 min listen
Biotech Women Striking at the Glass Ceiling: The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives. by I AM BIO
25 min listen
We Need Bees. Bees Need Biotech.: Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming. In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees. by I AM BIO
27 min listen
The Horseshoe Crab Saved Us. Can We Save the Horseshoe Crab?: The horseshoe crab has endured for over 450 million years. It has survived several mass extinctions including the one that killed off the dinosaurs. One reason for their incredible resiliency is their ability to fend off bacterial infection. Their blood contains cells that clot around invading bacteria, thereby protecting them from the attacking toxins. In this episode we talk with three experts about how this animal’s unique blue blood has become essential to modern medicine. We also talk about why horseshoe crab populations are dwindling, and what biotech is doing to address the shortfall. by I AM BIO
28 min listen
Stand Up for Science—The Fight Against Misinformation (Redux): Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech? (Redux): The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR (Redux): CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures (Redux): When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs (Redux): The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen
Cracking the Code on Pain Relief (Redux): Imagine living with excruciating pain that prevents you from walking or doing the things most of us take for granted. We all experience pain, and 50 million people cope with chronic, debilitating pain. The market for pain therapies is estimated at $74 billion. And yet, investment in new pain and addiction treatments is falling short of what is needed, according to a new BIO report, which shows a 44% decrease in clinical drug programs for pain over the past five years. Our guests on this episode talk about the challenges of living with and treating pain, as well as research and development on new, non-addictive and safer pain therapies. by I AM BIO
26 min listen
Why are Katie Couric and 15K People Headed to Boston?: During the last several decades Boston has become a biotech Mecca, with its Kendall Square attracting more than 120 biotech companies, both large and small. It is called the most innovative square mile on the planet. This June BIO will bring over 15,000 biotech leaders to Boston for its 2023 BIO International Convention. Speakers including award-winning journalist and health advocate, Katie Couric, will talk about how they will “Stand up for Science”—the Convention’s theme. MassBIO CEO, Kendalle Burlin O’Connell joins host, Rachel King in a wide-ranging discussion about how Boston became the largest biotech hub in the world. by I AM BIO
16 min listen
Stand Up for Science—The Fight Against Misinformation: Wading through the torrent of information available online is challenging for everyone. It can be hard to know what and whom to believe. We talk with the FDA Commissioner and other leaders on the frontlines of health and science about how to be more aware of false and misleading information, and its risks to our wellbeing and future innovation. And we discuss ways to stand up for science and stop the spread of misinformation. by I AM BIO
26 min listen
Is Space the Next Frontier for Biotech?: The International Space Station has been orbiting in lower earth since 1998 and has been continually inhabited since November 2000. The ISS was originally conceived as a staging base for future missions into deep space. As it turns out, lower earth orbit is an ideal setting for scientific research, from physics and meteorology to astronomy and the life sciences. In this episode we talk with three scientists whose projects are using lower earth orbit to deepen our knowledge of biotechnology and its benefits for mankind. by I AM BIO
27 min listen
The New Age of CRISPR: CRISPR has emerged as a powerful tool for altering DNA sequences with incredible precision, opening up new avenues of research into the treatment of disease. In this episode, we explore the science behind CRISPR, as well as its potential. From curing genetic disorders to creating new crop varieties, the possibilities seem endless. Our four guests today are scientists working to push these gene editing tools to the next frontier. by I AM BIO
28 min listen
Accelerating Hope: The Pathway for Cures: When people were dying from AIDS in the 1980s and 90s, Congress found a way to expedite the drug approval process and saved countless lives. Established in 1992, the Accelerated Approval Program allows the FDA to speed approval of drugs for patients with serious and life-threatening conditions. In this episode we talk with the father of children with a rare disease, a company CEO working to treat rare diseases and two policy experts on Accelerated Approval. by I AM BIO
23 min listen
Why AI and Biotech are BFFs: The convergence of Artificial Intelligence (AI) and biotechnology has emerged as one of the most exciting and transformative areas of science. Researchers are developing new tools and technology that could bring about breakthroughs to revolutionize the fields of medicine and health care. In this episode, we talk with scientists who are using AI to unlock new possibilities in the search for novel drugs, cures, and treatments. by I AM BIO
22 min listen

Related podcast episodes

Skip carousel

“Herd” Immunity: Biotech companies are working feverishly to develop antibody therapies to provide short-term protection against COVID-19. But what if the novel coronavirus mutates and outwits traditional monoclonal antibodies? Well, that’s where the super cows come in. Hosted by Jim Greenwood. by I AM BIO
36 min listen
To Plan B, Or Not To Plan B: With high numbers of Covid cases, should the government impose Plan B now? by 5 Live Science Podcast
55 min listen
DNA vaccines: a better path to taming the pandemic? by The BioWorld Insider Podcast
26 min listen
Bonus: Vaccines for dummies with Moderna President Dr. Stephen Hoge by Next Question with Katie Couric
53 min listen
#COVID19: The Quest for a Vaccine: What does finding a vaccine actually look like? Who’s involved? Last season on The Antigen we outlined the many steps it takes for a vaccine to go from discovery to distribution, in this episode we ask if that process can safely accelerate for COVID-19. We’ll also wrap up with the latest headlines on Pfizer's response to the crisis. by The Antigen
25 min listen
Are the Covid-19 vaccines safe?: What's in the coronavirus vaccine. Also, how maggots get into wounds, and ivermectin and Covid... by Ask the Naked Scientists
22 min listen
Coronapod: Why COVID antibody treatments may not be the answer: In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a var... by Nature Podcast
15 min listen
Coronavirus: A Vaccine, Then What? by Science Rules! with Bill Nye
21 min listen
The ESG Weekly: The ESG of vaccines, and shareholders say JPM must talk climate: There are some promising COVID‐19 vaccines in early human trails, but we have some questions if they are successful: Who will own the patent? Who will distribute them? Who will be responsible if something goes wrong? And then we discuss the recent proxy battle at JPMorgan that ended with some interesting wins for climate activists. by ESG now
19 min listen
CTT #33: Why aren’t we producing generic vaccines?: Moderna, Pfizer and now Johnson & Johnson have emerged as surprising heroes of the Covid-19 pandemic—pulling our nation out of this pandemic one vaccine shot at a time. This week, ... by Fixing Healthcare Podcast
43 min listen
#93 – Andy Weber on rendering bioweapons obsolete & ending the new nuclear arms race: <p>Andy Weber's current mission is to spread the word that while bioweapons are terrifying, scientific advances also leave them on the verge of becoming an outdated technology.<br></p> by 80,000 Hours Podcast
114 min listen
Episode 6: Gene editing: Since the arrival of Crispr in 2009, gene editing has made its way into labs. Its groundbreaking importance was acknowledged through the 2020 Nobel Prize in Chemistry. Expanding gene editing for medical treatments, Cellectis focuses its 20 years of exper... by A view on
10 min listen
Nick Conley – Chief Science Officer & Co-Founder of Epibiome – Combating Antibiotic Resistant Bacteria: EpiBiome, a microbiome engineering company based in San Francisco, is busy developing next generation antibacterials to fight a real problem; the growing threat of antibiotic resistant bacteria. Their focus is also… by Finding Genius Podcast
43 min listen
348: How product managers can help to future-proof organizations – with Jonathan Brill: Prepare for the unexpected as a product manager Today we are talking about change. Innovation itself means making change happen. Changes also come from external sources, with the COVID pandemic being an example of a huge cause of change. Our guest, by Product Mastery Now for Product Managers, Leaders, and Innovators
37 min listen
S2 E1: The COVID-19 Pandemic - Too Many Lies to Count: Dr. James Odell sheds light on the deception that has circulated during the COVID-19 pandemic. He also delves into the concerns related to mask-wearing, illuminates the numerous safety issues surrounding COVID-19 vaccinations, and offers suggestions... by The Science of Self-Healing
20 min listen
[BBUK] EP 31: Debunking 5G/COVID-19 conspiracies | Dr Jason Kindrachuk: In this episode of the Blood Brothers Podcast, Dilly Hussain speaks with assistant professor at the University of Manitoba, Dr Jason Kindrachuk. #Coronavirus #5G #COVID19 Dr Kindrachuk, who is a virologist at the Canada Research Chair, addresses... by The Mad Mamluks
68 min listen
Covid-19 Vaccines vs. The Bottom Line by Crash Course
41 min listen
#11: Is a COVID-19 vaccine almost ready?: The past week brought promising news from Moderna, a biotech company that announced the results of its early vaccine trials—an announcement that sent the firm’s stock price up 30%. However, ... by Fixing Healthcare Podcast
31 min listen
Founding Infinimmune & Developing Breakthrough Tools for Antibody Discovery with Wyatt McDonnell by Axial Podcast
57 min listen
COVID-19 Vaccine Distribution: Safety, Efficiency, Equity by Projectified
16 min listen
Statins and Nocebo, Vit D & Covid, new therapies for Covid: Research trials for Covid-19. Do vitamin D supplements prevent infection from SARS-COV-2? by Inside Health
28 min listen
182: What's the Deal with Ivermectin? (w/ Dr. Eric Osgood MD): Dr. Eric Osgood MD, an internal medicine doctor who formerly consulted with Front Line COVID-19 Critical Care Alliance (FLCCC) joins DOOMED with Matt Binder to breakdown what is Ivermectin and why has it become such a hot button issue with some people consuming a horse paste to treat COVID-19. We breakdown all the misinformation and fake news, discuss why taking the COVID-19 vaccine is the best thing you can do to protect yourself from COVID, why some doctors are seriously looking at Ivermectin in the fight against the coronavirus, what the drug is typically used for, how anti-vaxxers have dangerously resorted to taking the horse paste version of Icvermectin, how Ivermectin has strangely become an identity for some, the bizarre false studies that have been used to promote Ivermectin, why he left the FLCCC, a now-controversial group that's been promoting Ivermectin use, and the unfortunate turn Dr. Kory Pierre of the group h by DOOMED with Matt Binder
96 min listen
The Interview - Inside the COVID-19 Vaccine Project w/ Dr. Kayvon Modjarrad: Dr. Kayvon Modjarrad explains what the Department of Defense's coronavirus vaccine research project is doing to combat the pandemic. by Real Vision Daily Briefing: Finance & Investing
62 min listen
738: Engineering Biomaterials with Generative AI, with Dr. Pierre Salvy: Bioengineering and Generative AI converge under t… by Super Data Science: ML & AI Podcast with Jon Krohn
23 min listen
E60: Editor’s Picks May 2022: Join us as we go through the JEADV Editor's Picks of May 2022: (1) Overlapping pathogenesis of atopic dermatitis and Covid-19: is monoclonal antibody treatment appropriate? (2) Is tertiary syphilis on the rise? A rare case from Japan (3) Acute neurologic... by EADV Podcast
9 min listen
24: Puppies: Dr. Don and Professor Ben talk about the microbiological risks from puppies. Dr. Don - not risky ?? Professor Ben - not risky ?? by Risky or Not?
7 min listen
Covid Milestones: Eli Lilly CEO on Antiviral Approval, Pfizer’s FDA Application, & Getting Back to the Movies: Pfizer is submitting its application to the FDA for emergency use of its Covid-19 vaccine. If approved, administration of the vaccine could begin before the end of the year. The FDA has approved emergency use of Eli Lilly’s arthritis drug baricitinib in combination with Gilead’s remdesivir to treat Covid-19 patients. Eli Lilly CEO David Ricks and CNBC’s Meg Tirrell discuss distribution, supply, and the path to approval for coronavirus treatments. Plus, IMAX CEO Richard Gelfond is planning ahead for theater reopenings around the world. He shares his own outlook for entertainment, in-person movies, and safety post-pandemic. by Squawk Pod
24 min listen
How Innovations in Genomics and Biotech Can Help Us With The COVID-19 Crisis: As the coronavirus (COVID-19) continues to strengthen its grip across the globe, it’s natural to feel a sense of dread and despair. However, we believe that tumultuous times can be the best catalysts for innovation, and this pandemic is no exception. by FYI - For Your Innovation
29 min listen
Listening to this podcast is good for the community, the industry and your bottom line: Jacob Braude, a principal at ZS, returns to the podcast to discuss his firm's latest research on vaccine hesitancy. Mentioned in this episode: The real reason people don't get vaccinated for COVID-19? They don't feel like it. A cognitive research p... by HFMA’s Voices in Healthcare Finance
27 min listen
Was Omicron Man-Made? What Is the End Result of Mass Injection? | Guest: Dr. Ryan Cole | 12/6/21 by Conservative Review with Daniel Horowitz
72 min listen

Discover this podcast and so much more

“Herd” Immunity (Redux)

“Herd” Immunity (Redux)

Description

Titles in the series (100)

More Episodes from I AM BIO

Related podcast episodes